### Edgar Filing: AVEO PHARMACEUTICALS INC - Form 4

#### AVEO PHARMACEUTICALS INC

Form 4 October 04, 2013

## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

**OMB** 3235-0287 Number:

Check this box if no longer subject to Section 16.

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

January 31, Expires: 2005

0.5

**OMB APPROVAL** 

Estimated average burden hours per

response...

Form 4 or Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person \* 5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading HA NGOC TUAN Issuer Symbol AVEO PHARMACEUTICALS INC (Check all applicable) [AVEO] (Last) (First) (Middle) 3. Date of Earliest Transaction \_X\_ Director 10% Owner Other (specify X\_ Officer (give title (Month/Day/Year) below) C/O AVEO PHARMACEUTICALS, 10/02/2013 Chief Executive Officer INC., 75 SIDNEY STREET (Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check Filed(Month/Day/Year) Applicable Line) \_X\_ Form filed by One Reporting Person Form filed by More than One Reporting CAMBRIDGE, MA 02139 Person

(City)	(State)	Zip) Table	I - Non-D	erivative Se	curitie	es Acqu	iired, Disposed of	, or Beneficiall	y Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date any (Month/Day/Year)		Code (Instr. 8)	n(A) or Disp (Instr. 3, 4 a	A) or Disposed of (D) instr. 3, 4 and 5)  (A) or		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	09/06/2013		Code V  J	Amount 118,187	(D) A (1)	Price \$ 0	,	D	
Common Stock	09/06/2013		J	118,187	D (3)	\$0	0	I	Held by GRAT (4)
Common Stock	10/02/2013		D(5)	137,500	D	\$0	381,568	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of **SEC 1474** information contained in this form are not (9-02)required to respond unless the form

## Edgar Filing: AVEO PHARMACEUTICALS INC - Form 4

# displays a currently valid OMB control number.

9. Nu Deriv Secur Bene Own Follo Repo Trans (Instr

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<ol> <li>Title of</li> </ol>	2.	3. Transaction Date	3A. Deemed	4.	5.	<ol><li>Date Exerc</li></ol>	cisable and	7. Titl	le and	8. Price of	9
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transaction	orNumber	Expiration Da	ate	Amou	int of	Derivative	J
Security	or Exercise		any	Code	of	(Month/Day/	Year)	Under	lying	Security	,
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Derivative	e		Secur	ities	(Instr. 5)	]
	Derivative				Securities			(Instr.	3 and 4)		(
	Security				Acquired						]
					(A) or						]
					Disposed						-
					of (D)						(
					(Instr. 3,						
					4, and 5)						
									Amount		
									or		
						Date	Expiration	Title	Number		
						Exercisable	Date		of		
				Code V	(A) (D)				Shares		

## **Reporting Owners**

Reporting Owner Name / Address			Televisinps	
	Director	10% Owner	Officer	Other

HA NGOC TUAN C/O AVEO PHARMACEUTICALS, INC. 75 SIDNEY STREET CAMBRIDGE, MA 02139

X

Chief Executive Officer

Relationshine

# **Signatures**

/s/ Joseph D. Vittiglio, attorney-in-fact

10/04/2013

\*\*Signature of Reporting Person

Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The increase of shares of directly held common stock was due to a distrubition from the Tuan Ha-Ngoc 2009 GRAT to the reporting person on September 6, 2013.
- (2) Includes 3094 shares acquired on June 28, 2013 under the AVEO Pharmaceuticals, Inc. Employee Stock Purchase Plan.
- (3) The decrease of shares of indirectly held common stock was due to a distribution from the Tuan Ha-Ngoc 2009 GRAT to the reporting person on September 6, 2013.
- (4) Shares were held by Gabriel Schmergel, Trustee, or his successor in trust, of the Tuan Ha-Ngoc 2009 GRAT.
- Shares underlying such disposition to the issuer were forfeited by the reporting person pursuant to the terms of two awards of restricted stock granted to the reporting person on January 31, 2012 and January 24, 2013 in connection with the determination of the issuer's Compensation Committee that certain specified strategic performance objectives were not met.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Reporting Owners 2

# Edgar Filing: AVEO PHARMACEUTICALS INC - Form 4

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.